The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Experimental Drug Combination Curbs Chikungunya Arthritis in Mice

Experimental Drug Combination Curbs Chikungunya Arthritis in Mice

May 16, 2017 • By Bryn Nelson, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
fi3/shutterstock.com

fi3/shutterstock.com

Doctors have had few options to treat the chronic rheumatoid arthritis-like symptoms associated with chikungunya virus infections beyond over-the-counter pain relievers. A recent study in Science Translational Medicine has spurred new optimism by finding that a combination therapy—the anti-rheumatic drug abatacept paired with a chikungunya-neutralizing monoclonal antibody—abolished acute symptoms in infected mice.1

You Might Also Like
  • Cytokine Response Provides Clues to Chikungunya Sequelae
  • Chikungunya Fever May Trigger Chronic Articular Symptoms
  • Rheumatology Drug Updates: Labeling for Fluoroquinolones; FDA to Review Benzhydrocodone/Acetaminophen Combination
Explore This Issue
May 2017
Also By This Author
  • How Obamacare Is Expected to Impact Rheumatologists and Their Patients

The strategy must clear multiple hurdles before it can become a viable intervention in human patients. Mark Heise, PhD, a geneticist who studies viral pathogenesis at the University of North Carolina in Chapel Hill, cautions that the course of a chikungunya infection differs between humans and mice, the latter of which aren’t natural hosts for the virus. Even so, Dr. Heise, who wasn’t involved with the new study but previously collaborated with one of its co-authors, calls it “an important advance” for the field. “I think it’s a really good stepping off point for thinking about these sort of combination therapies,” he says, “especially for people who may be at risk for developing chronic disease manifestations.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Background

Mosquito-borne chikungunya, which debuted in the Western Hemisphere in late 2013, has since sickened more than 1.8 million people in the Americas. Apart from a few cases in southern Florida, however, the thousands of chikungunya infections seen in the U.S. to date have all been acquired outside the country.

Jonathan Miner, MD, PhD, the new study’s lead author and an instructor in medicine at Washington University in St. Louis, previously showed that the virus can cause joint pain and swelling that bears a striking resemblance to rheumatoid arthritis.2 The travel history of patients, he emphasizes, can be critical in distinguishing between the two diseases.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

From animal studies of the viral infection’s acute phase, chikungunya seems to replicate to high levels within the blood and then invades the joints, where it can replicate as well. Within three days of infection, human patients can exhibit symptoms such as a high fever, joint pain, morning stiffness and inflammation. “I’ve seen patients who had such severe pain that they were unable to walk. It can be really debilitating,” Dr. Miner says. Patients may also experience muscle pain, a rash and conjunctivitis.

Arthritis, however, is chikungunya’s signature symptom, appearing in about 90% of cases. Roughly 60% of patients continue having symptoms a year or more after the infection—well after the virus is no longer detectable in the blood.

The Study

Dr. Miner and co-author Deborah Lenschow, MD, PhD, an associate professor of medicine and fellow rheumatologist at Washington University, began studying the virus and its effects when multiple patients began showing up at their rheumatology clinic in 2014 complaining of severe joint and muscle pain.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Drug Updates Tagged With: abatacept, anti-rheumatic drug, chikungunya, chronic arthritis, Infection, mosquito, mouse model, patient care, Research, Rheumatic Disease, Rheumatoid arthritis, rheumatology, study, symptom, TreatmentIssue: May 2017

You Might Also Like:
  • Cytokine Response Provides Clues to Chikungunya Sequelae
  • Chikungunya Fever May Trigger Chronic Articular Symptoms
  • Rheumatology Drug Updates: Labeling for Fluoroquinolones; FDA to Review Benzhydrocodone/Acetaminophen Combination
  • Chikungunya Arthritis

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.